Suppr超能文献

中国 2020-2021 年 SARS-CoV-2 大流行期间的造血干细胞移植活动:来自中国血液和骨髓移植登记组的报告。

Hematopoietic Stem Cell Transplantation Activity in China 2020-2021 During the SARS-CoV-2 Pandemic: A Report From the Chinese Blood and Marrow Transplantation Registry Group.

机构信息

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.

Hebei Yanda Lu Daopei Hospital & Beijing Ludaopei Hospital, Langfang, Hebei & Beijing, China.

出版信息

Transplant Cell Ther. 2023 Feb;29(2):136.e1-136.e7. doi: 10.1016/j.jtct.2022.11.011. Epub 2022 Nov 17.

Abstract

Between 2020 and 2021, 31,525 hematopoietic stem cell transplantations (HSCTs) were reported to the Chinese Blood and Marrow Transplantation Registry Group throughout mainland China. In this report, we describe the activity and current trends for HSCT in China during the SARS-CoV-2 pandemic. In 2020, a total of 13,415 cases of HSCT were reported from 166 transplantation teams, and 75% (10,042 cases) were allogeneic HSCTs. In 2021, a total of 18,110 cases of HSCT were reported from 174 transplantation teams, and 70% (12,744 cases) were allogeneic HSCTs. Haploidentical donor (HID) transplantation accounted for 63% (7977 cases) of allogeneic HSCTs in 2021. The most common indications for allogeneic HSCT for malignant disease were acute myeloid leukemia (37%) and acute lymphoblastic leukemia (23%), and the largest proportion of nonmalignant disease comprised aplastic anemia (13%). The peripheral blood stem cell source accounted for 41% of HIDs and 75% of matched sibling donors. The BuCy-based regimen (57%) was the most popular conditioning regimen for allogeneic HSCT, followed by the BuFlu-based regimen (28%) and total body irradiation-based regimen (11%). This survey provides comprehensive information about the current activities and might benefit clinical physicians' decision planning for HSCT.

摘要

2020 年至 2021 年,中国大陆共有 31525 例造血干细胞移植(HSCT)向中国血液和骨髓移植登记组报告。在本报告中,我们描述了 SARS-CoV-2 大流行期间中国 HSCT 的活动和当前趋势。2020 年,共有 166 个移植团队报告了 13415 例 HSCT,其中 75%(10042 例)为异基因 HSCT。2021 年,共有 174 个移植团队报告了 18110 例 HSCT,其中 70%(12744 例)为异基因 HSCT。2021 年,HID 移植占异基因 HSCT 的 63%(7977 例)。异基因 HSCT 治疗恶性疾病最常见的适应证为急性髓细胞白血病(37%)和急性淋巴细胞白血病(23%),非恶性疾病中最大的比例为再生障碍性贫血(13%)。异基因 HSCT 的外周血干细胞来源占 HID 的 41%,占同胞供者的 75%。BuCy 方案(57%)是异基因 HSCT 最常用的预处理方案,其次是 BuFlu 方案(28%)和全身照射方案(11%)。该调查提供了有关当前活动的全面信息,可能有益于临床医生对 HSCT 的决策规划。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16a4/9671625/bcc5c10baa29/gr1_lrg.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验